Pangea Biomed Joins Second Phase of LiquidBX Consortium to Improve Cancer Detection and Treatment Response Prediction

Pangea Biomed, the startup behind the advanced cancer response prediction platform ENLIGHT, today announced its participation in the next phase of the LiquidBX consortium. Funded by the Israel Innovation Authority (IIA), this consortium brings together technology companies, hospitals and leading research labs to advance liquid biopsy technologies for early cancer detection, disease monitoring, and treatment choice.

In its second phase, the LiquidBX consortium will focus on cancer monitoring and treatment response prediction. It will gather multi-modal omics data using seven technologies for over 1,000 solid cancer patients at Hadassah University Hospital Ein-Kerem. Alongside Pangea, industry participants include Senseera, Identifai, Minovia, Salignostics, and MS Tech.

“Cancer is a very complex disease, and fighting it requires a 360-degree attack. Each consortium member brings its unique angle and tools, and we share data and results that would be very difficult for a single company to achieve alone,” said Tuvik Beker, CEO of Pangea Biomed. “This is a tremendous power multiplier in our ability to deliver effective solutions quickly.”

In the first phase of the consortium, Pangea contributed by developing a software component that extracts features from RNA data, representing the activation state of thousands of genetic interactions. This tool demonstrated high accuracy in distinguishing tumors from healthy tissue and laid the groundwork for future research by ensuring consistency across different RNA measurement platforms.

Pangea aims to apply these proven approaches to liquid biopsies, seeking proof of concept for two new technologies: monitoring patient status following treatment, for early indication of treatment success or failure, and predicting response to different therapy options to choose the optimal therapy.

To achieve this, Pangea will take on two leading roles in this phase:

• Analyzing all mRNA expression data, harmonizing and normalizing it and contributing the processed data to the consortium.

• Leveraging the ENLIGHT platform to extend the consortium’s focus beyond cancer detection to monitoring and predicting treatment response. Pangea will develop biomarkers for treatment response prediction before clinical data accumulation and validate these biomarkers once patient outcome data becomes available.

“We are thrilled to see the LiquidBX consortium entering its next phase, where technology companies and research labs combine forces to push the boundaries of liquid biopsy performance,” said Ronen Sadeh, CEO of Senseera and consortium chairman. “This partnership exemplifies the power of collaborative innovation.”

Together, the Consortium will create a unique, comprehensive dataset featuring over 1,000 cases and more than seven different omics readouts per sample, offering unprecedented insights into cancer biology.

“The Israel Innovation Authority is proud to support the LiquidBX consortium, recognizing this as an important field with significant potential,” said Dr. Alon Stopel, Chairman of the IIA and Chief Scientist for Innovation at the Ministry of Innovation, Science and Technology. “The success of this consortium underscores the importance of innovative partnerships in driving forward our national healthcare priorities.”

This partnership builds upon Pangea Biomeds’ existing collaboration with the Hadassah University Hospital Ein-Kerem to improve the accuracy and effectiveness of solid tumor cancer treatment predictions through advanced genetic and transcriptomic profiling for over 2,000 patients annually.

To learn more about Pangea Biomed’s technology, please visit PangeaBiomed.com.

About Pangea Biomed:

Founded in 2018, Pangea Biomed developed ENLIGHT – the world’s most advanced multi-cancer, multi-therapy response predictor. By combining machine learning and deep RNA analysis, the company is mapping tumor molecular signatures to dynamically and adaptively personalize cancer care for a healthier world. Pangea aims to bring effective precision oncology to cancer patients, improve oncology drug development and empower oncologists to treat patients with success. Pangea is backed by NFX, and its technology has been published in leading journals, including Cell, Med, Science Advances, Cancer Cell, Journal for ImmunoTherapy of Cancer and Nature Communications.

Contact Information

VSC for Pangea Biomed

Media Contact

VSC for Pangea Biomed

pangea@vsc.co